Elisabetta Chiarparin is currently Section Head of Oncology Chemistry UK and head of Oncology PROTAC platform. Elisabetta has almost 20 years drug discovery experience in the CNS and Oncology therapeutic areas, gained at GlaxoSmithKline, Astex Pharmaceuticals and AstraZeneca. She has led structural, computational and medicinal chemistry teams and contributed to the development of several preclinical and clinical candidates. She is passionate about drugging the ‘difficult to drug targets’ and of Structure Based Drug Design. Elisabetta is co-author of over 50 publications, patents, posters, and oral presentations. Elisabetta was nominated lecturer for 2020/2021 by the of Royal Society of Chemistry Biological and Medicinal Chemistry Sector (BMCS) lectureship. Elisabetta holds a Ph.D. in chemistry from the University of Lausanne, Switzerland.
Dr Andy Merritt has held the post of Head of Chemistry at the LifeArc (formerly MRC Technology) Centre for Therapeutics Discovery (CTD) since the summer of 2009. In close collaboration with academic scientists, the CTD develops and subsequently prosecutes innovative drug discovery programmes emerging from academic research, in oncology, neuroscience and diseases of the developing world. Prior to his current position, Andy was a Director of Discovery Medicinal Chemistry at GlaxoSmithKline. Andy joined the former Glaxo organization as a senior medicinal chemist in 1988 following postdoctoral studies in the US. Andy sat on the RSC Chemistry World editorial board between 2003 and 2019, has been a regular undergraduate lecturer in pharmaceutical medicine at Imperial College, Warwick and Sussex universities, and was the industrial organiser for the RSC Medicinal Chemistry residential summer school between 1999 and 2005.